Author: Sleep Review Staff

Risk Evaluation and Mitigation Strategies (REMS) for Cephalon’s medications Nuvigil (armodafinil) Tablets [C-IV] and Provigil (modafinil) Tablets [C-IV] have been approved by the US Food and Drug Administration (FDA). Both the Nuvigil and

In a letter dated last month, and obtained by the Politico Web site, 12 members of Congress ask FDA Commissioner Margaret A. Hamburg, MD, for some specific changes, including a "more detailed work schedule for implementing recommendations,